Overview
Discounted cash flow
Income / accounting-based
Multiples & assets
Scenario
Toolbox
Weighted blend
$386.16
+166.43% vs spot
Strong Buy
Spot price
$144.94
Mkt cap $10.04B
subtle cardAnalyst PT consensus
$339.00
+133.89% vs spot
subtle cardMethods covered
15 / 16
14 in blend
subtle cardFootball field
PODD · fair-value range by method
Method comparison
PODD · fair value by valuation framework
| Method | Category | Fair value | Range | vs spot | Weight | Driver | Conf. |
|---|---|---|---|---|---|---|---|
| DCF · FCFF | dcf | $1,000.52 | $443.81 – $2,398.02 | +590.30% | 23.7% | WACC 8.0%, g₀=25.0%, gₗ=7.0% | high |
| DCF · FCFE | dcf | $309.82 | $199.81 – $552.26 | +113.76% | 17.8% | kₑ 9.8%, g₀=25.0%, gₗ=7.0% | high |
| Residual income | income | $20.94 | $18.43 – $23.45 | -85.55% | 11.8% | BV 18.11, ROE 16.3% → kₑ | high |
| EVA / MVA | income | $675.41 | $594.36 – $756.46 | +365.99% | 8.3% | IC 1.8B, WACC 8.0% | high |
| P/E · sector | multiple | $76.56 | $67.37 – $85.75 | -47.18% | 14.2% | EPS 3.48 × peer P/E 22.0 | med |
| P/S · sector | multiple | $129.50 | $110.08 – $148.93 | -10.65% | 3.6% | Rev/sh 32.38 × peer P/S 4.00 | med |
| EV / EBITDA | multiple | $101.24 | $89.09 – $113.39 | -30.15% | 11.8% | EBITDA × peer 15.0× − ND 0.3B | high |
| EV / EBIT | multiple | $97.95 | $83.26 – $112.65 | -32.42% | 2.4% | EBIT × peer 18.0× − ND | med |
| EV / Sales | multiple | $106.07 | $90.16 – $121.98 | -26.82% | 2.4% | Sales × peer 3.40× − ND | med |
| PEG-anchored | multiple | $139.20 | $118.32 – $160.08 | -3.96% | 1.2% | PEG=1, fwd EPS g 86.3% | med |
| Earnings power | intrinsic | $47.25 | $41.58 – $52.92 | -67.40% | 0.6% | NOPAT / WACC, no growth | med |
| Graham revised | intrinsic | $166.51 | $141.53 – $191.49 | +14.88% | 0.6% | EPS×(8.5+2g)·4.4/Y | low |
| Lynch P/E=g | intrinsic | $87.00 | $73.95 – $100.05 | -39.98% | 0.6% | PE = g (25.0) | low |
| Book NAV | asset | $18.11 | $17.21 – $19.02 | -87.50% | 1.2% | (Assets − Liabilities) / Shares | high |
| Liquidation | asset | $9.24 | $7.85 – $10.63 | -93.62% | — | Cash 100% + non-cash 70% − Liab. | low |
| Reverse DCF | reverse | — | — | — | — | Implied g -19.5% · Pessimistic — market pricing decline | high |
Cost-of-capital build-up
CAPM cost of equity, after-tax cost of debt, WACC. Risk-free as of 2026-05-12.
| Risk-free rate (US 10y Treasury)rf | 4.46% |
| Equity beta (1.20)β | × 1.20 |
| Equity risk premiumERP | 4.46% |
| Cost of equity (CAPM)kₑ | 9.80% |
| Pre-tax cost of debtkd | 7.58% |
| Effective tax ratet | 27.2% |
| After-tax cost of debt | 5.52% |
| Equity weight$1.5B | 59.0% |
| Debt weight$1.1B | 41.0% |
| WACC | 8.05% |
Growth assumptions
Blended forward growth used as DCF default; terminal pegged to long-run nominal GDP.
| Analyst forward revenue growthFMP | 22.99% |
| Analyst forward EPS growthFMP | 86.32% |
| Historical 5y revenue CAGRFY | 25.30% |
| Historical 5y EPS CAGRFY | 93.16% |
| Sustainable g (ROE × retention)Δ | 16.31% |
| Blended near-term growth (g₀) | 25.00% |
| Terminal growth (gₗ) | 7.00% |
Sources
- FMP /analyst-estimates— 8 rows(as of 2023-12-31)
- Treasury rates · 10y— 4.46% rf(as of 2026-05-12)
- market_risk_premium · DB— 4.46% ERP(as of 2026-05-13)
- Sector multiple defaults— Healthcare (live sector PE unavailable)
- FMP /price-target-consensus— mean $339.00
This page is generated by a quantitative valuation engine for research purposes only and does not constitute investment advice. Methodology follows standard CFA / Damodaran frameworks; assumptions are driven by analyst consensus from Financial Modeling Prep and reported financial statements.